logo
Plus   Neg
Share
Email
Comment

Watson Laboratories Files ANDA To Market Nebivolol Hydrochloride Tablets

Watson Laboratories Inc., a subsidiary of Watson Pharmaceuticals Inc. (WPI), has filed an Abbreviated New Drug Application with the FDA seeking approval to market Nebivolol Hydrochloride Tablets, the generic version of Forest Laboratories' Bystolic.

Bystolic is a beta-adrenergic blocking agent that is approved for the treatment of hypertension.

Forest Laboratories filed suit against Watson on March 13 in the US District Court of Delaware seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent.

Watson said it might be the first applicant to file an ANDA for the generic version of Bystolic and if approved it will be entitled to 180 days of generic market exclusivity.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After months of bickering, Aurora Cannabis and CanniMed Therapeutics are moving close to a game-changing merger in Canada's red-hot marijuana sector. The big hangup was Aurora's insistence that CanniMed not overpay for smaller rival NewStrike. However, Aurora in its urgency to get the deal done... Budweiser, which has been reigning as the 'king of beers' is now number 4 in sales in U.S. Budweiser lost to Miller Lite in 2017, according to Beer Marketer's Insights, the publication focused on beer industry statistics. Activist investor Bill Ackman's hedge fund Pershing Square Capital Management L.P. is cutting ten employees from its workforce, according to media reports, citing people with knowledge of the matter. The job cuts on Friday have reportedly brought the New York-based company's head count down to 46 and were mostly in the hedge fund's back-office and support staff.
comments powered by Disqus
Follow RTT